Table 5.
Univariate and multivariate analysis for non-invasive mechanical ventilation, tracheal intubation, CRRT, and ARDS in COVID-19 patients with GI symptoms.
| Hazare ratio | 95%CI | p-value | |
|---|---|---|---|
| ARDS | |||
| Unadjusted | 2.7 | 1.9–3.9 | <0.001 |
| Adjusted I | 2.8 | 1.7–4.6 | <0.001 |
| Adjusted II | 2.9 | 1.8–5.0 | <0.001 |
| Non-invasive mechanical ventilation | |||
| Unadjusted | 2.6 | 1.7–4.0 | <0.001 |
| Adjusted I | 3.1 | 1.8–5.4 | <0.001 |
| Adjusted II | 3.3 | 1.9–5.7 | <0.001 |
| Tracheal intubation | |||
| Unadjusted | 3.2 | 1.6–6.5 | 0.001 |
| Adjusted I | 2.4 | 1.1–5.5 | 0.037 |
| Adjusted II | 2.5 | 1.1–6.0 | 0.035 |
| CRRT | |||
| Unadjusted | 7.1 | 1.5–34.4 | 0.015 |
| Adjusted I | 5.1 | 0.5–53.0 | 0.175 |
| Adjusted II | 6.1 | 0.5–71.3 | 0.149 |
Adjust I model adjusting for Lymphocyte, PLT, Albumin, Urea, Creatinine, LDH, PT, APTT, D-dimer, CRP, and Procalcitonin; Adjust II model adjusting by variables in Adjust I model plus antiviral treatment, antibiotics, and corticosteroids. CRRT, continuous renal replacement therapy; ARDS, acute respiratory distress syndrome.